{"nctId":"NCT01763918","briefTitle":"Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2","startDateStruct":{"date":"2013-02-07","type":"ACTUAL"},"conditions":["Hyperlipidemia"],"count":331,"armGroups":[{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Placebo QM","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Evolocumab Q2W","type":"EXPERIMENTAL","interventionNames":["Biological: Evolocumab"]},{"label":"Evolocumab QM","type":"EXPERIMENTAL","interventionNames":["Biological: Evolocumab"]}],"interventions":[{"name":"Evolocumab","otherNames":["AMG 145","Repatha"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female ≥ 18 to ≤ 80 years of age\n* Diagnosis of heterozygous familial hypercholesterolemia\n* On a stable dose of an approved statin and lipid regulating medication\n* Fasting LDL-C ≥ 100 mg/dL (2.6 mmol/L)\n* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)\n\nExclusion Criteria:\n\n* Homozygous familial hypercholesterolemia\n* LDL or plasma apheresis\n* New York Heart Association (NYHA) III or IV heart failure\n* Uncontrolled cardiac arrhythmia\n* Uncontrolled hypertension\n* Type 1 diabetes, poorly controlled type 2 diabetes\n* Uncontrolled hypothyroidism or hyperthyroidism","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in LDL-C at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.02","spread":"2.49"},{"groupId":"OG001","value":"5.53","spread":"3.25"},{"groupId":"OG002","value":"-61.25","spread":"1.77"},{"groupId":"OG003","value":"-55.74","spread":"2.25"}]}]}]},{"type":"PRIMARY","title":"Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"2.41"},{"groupId":"OG001","value":"2.30","spread":"2.41"},{"groupId":"OG002","value":"-61.23","spread":"1.71"},{"groupId":"OG003","value":"-63.25","spread":"1.70"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in LDL-C at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"4.2"},{"groupId":"OG001","value":"-1.3","spread":"4.1"},{"groupId":"OG002","value":"-101.7","spread":"3.0"},{"groupId":"OG003","value":"-98.8","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in LDL-C at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.5","spread":"4.2"},{"groupId":"OG001","value":"4.1","spread":"5.2"},{"groupId":"OG002","value":"-101.3","spread":"3.0"},{"groupId":"OG003","value":"-87.2","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"1.9","spread":null},{"groupId":"OG002","value":"67.0","spread":null},{"groupId":"OG003","value":"80.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.2","spread":null},{"groupId":"OG002","value":"68.3","spread":null},{"groupId":"OG003","value":"63.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"2.29"},{"groupId":"OG001","value":"2.72","spread":"2.21"},{"groupId":"OG002","value":"-55.79","spread":"1.63"},{"groupId":"OG003","value":"-57.28","spread":"1.56"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"2.40"},{"groupId":"OG001","value":"5.29","spread":"2.94"},{"groupId":"OG002","value":"-56.19","spread":"1.71"},{"groupId":"OG003","value":"-49.67","spread":"2.04"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"2.10"},{"groupId":"OG001","value":"2.21","spread":"1.97"},{"groupId":"OG002","value":"-49.58","spread":"1.48"},{"groupId":"OG003","value":"-52.76","spread":"1.36"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.67","spread":"2.32"},{"groupId":"OG001","value":"4.60","spread":"2.70"},{"groupId":"OG002","value":"-49.75","spread":"1.63"},{"groupId":"OG003","value":"-44.81","spread":"1.80"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"2.05"},{"groupId":"OG001","value":"4.14","spread":"2.13"},{"groupId":"OG002","value":"-45.74","spread":"1.45"},{"groupId":"OG003","value":"-45.02","spread":"1.50"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"2.19"},{"groupId":"OG001","value":"7.11","spread":"3.13"},{"groupId":"OG002","value":"-45.95","spread":"1.56"},{"groupId":"OG003","value":"-38.32","spread":"2.15"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"2.21"},{"groupId":"OG001","value":"1.65","spread":"2.35"},{"groupId":"OG002","value":"-52.39","spread":"1.56"},{"groupId":"OG003","value":"-53.91","spread":"1.60"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.54","spread":"2.49"},{"groupId":"OG001","value":"4.23","spread":"3.66"},{"groupId":"OG002","value":"-52.74","spread":"1.75"},{"groupId":"OG003","value":"-45.31","spread":"2.42"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.34","spread":"2.97"},{"groupId":"OG001","value":"5.35","spread":"2.95"},{"groupId":"OG002","value":"-24.03","spread":"2.09"},{"groupId":"OG003","value":"-25.65","spread":"2.07"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.68","spread":"3.27"},{"groupId":"OG001","value":"6.69","spread":"3.16"},{"groupId":"OG002","value":"-22.89","spread":"2.31"},{"groupId":"OG003","value":"-21.55","spread":"2.17"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.09","spread":"3.02"},{"groupId":"OG001","value":"7.49","spread":"3.26"},{"groupId":"OG002","value":"-13.27","spread":"2.14"},{"groupId":"OG003","value":"-9.25","spread":"2.27"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.50","spread":"3.51"},{"groupId":"OG001","value":"6.43","spread":"4.15"},{"groupId":"OG002","value":"-16.09","spread":"2.49"},{"groupId":"OG003","value":"-5.13","spread":"2.84"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"1.70"},{"groupId":"OG001","value":"-2.86","spread":"1.84"},{"groupId":"OG002","value":"7.93","spread":"1.20"},{"groupId":"OG003","value":"6.62","spread":"1.29"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.15","spread":"1.91"},{"groupId":"OG001","value":"-3.73","spread":"2.35"},{"groupId":"OG002","value":"8.05","spread":"1.35"},{"groupId":"OG003","value":"5.35","spread":"1.62"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.66","spread":"2.90"},{"groupId":"OG001","value":"6.34","spread":"3.27"},{"groupId":"OG002","value":"-13.97","spread":"2.06"},{"groupId":"OG003","value":"-9.20","spread":"2.27"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in VLDL-C at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.73","spread":"3.50"},{"groupId":"OG001","value":"4.10","spread":"4.17"},{"groupId":"OG002","value":"-17.25","spread":"2.48"},{"groupId":"OG003","value":"-5.06","spread":"2.84"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":54},"commonTop":["Nasopharyngitis","Headache","Arthralgia","Back pain","Dizziness"]}}}